tbuckley/cabot-search huggingface dataset:
Relationship between the detection rate of EpCAM-positive circulating tumor cells (CTCs) in metastatic breast cancer patients and the CTC enrichment technology.
Authors: R. Königsberg, G. Pfeiler, E. Obermayr, M. Gneist, R. Ruckser, M. Hudec, R. Zeillinger, C. Dittrich
Journal: Journal of Clinical Oncology (2010)

e21066 Background: Immunomagnetic EpCAM-based methods are successfully used to enrich and enumerate circulating tumor cells (CTCs) in metastatic breast cancer patients (mBC pat). In vitro data raised concerns whether EpCAM dependent CTC assays may enrich EpCAM negative (EpCAM-) CTCs. Methods: Tumor cells were identified with the anticytokeratin antibody, A45-B/B3. (i) We evaluated the EpCAM expression of 3 cell lines MCF-7, ZR-75-1 and Hs587T with flow cytometry. (ii) An anti-EpCAM immunomagnetic enrichment method, MACS HEA MicroBeads (MACS) was compared to a non-anti-EpCAM based new density centrifugation method, OncoQuick plus (OQ+), using spiking experiments. (iii) To validate these data in vivo, peripheral blood from 26 mBC pat was collected to compare the two methods. (iv) To explore EpCAM expression of the respective patients' CTCs, blood was enriched with the OQ+ procedure. An aliquot of enriched blood was immunocytochemically stained with a fluorescence-labeled EpCAM antibody. The other aliquot was used to verify EpCAM expression with RT-qPCR. Results: (i) MCF-7 and ZR-75-1 cell lines showed a strong (>90%), Hs587T tumor cells had a low (< 5%) or no EpCAM expression, respectively. (ii) MACS recovered significantly more of a definite number of spiked tumor cells than OQ+ in EpCAM positive (EpCAM+) cell lines (p = 0.002 and p = 0.007, respectively). OQ+ recovered significantly more EpCAM- Hs587T cells (p < 0.0001). (iii) With MACS 42.3% of mBC pat. had CTCs detected (median 0). With OQ+ CTCs were spotted in 69.2% of pat (median 8). The positivity rate of detected CTCs did not differ significantly between MACS and OQ+ (p = 0.065). A significantly higher number of CTCs was enumerated with OQ+ (p = 0.018). (iv) Irrespectively of the EpCAM detection method, 19% of mBC pat had EpCAM+ CTCs. MACS detected significantly (p = 0.001) more EpCAM+ CTCs. No association was found between CTCs detected by OQ+ and their EpCAM expression. Conclusions: The CTC enrichment method should be chosen according to the respective CTCs' EpCAM expression. Further investigations have to determine whether the accuracy of prognostication of mBC pat depends on the detection of EpCAM± CTC subpopulations. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration AstraZeneca
The Genomic and Epigenomic Landscapes of Blast Crisis Transformation in Chronic Myeloid Leukemia
Authors: S. Tiong Ong, Thushangi Pathiraja, Asif Javed, Xin Xuan Sheila Soh, Simeen Malik, Joanna H.J. Tan, Tun Kiat Ko, Charles Chuah, Naoto Takahashi, Ravi Bhatia, King Pan Ng, Wee Joo Chng, Chandana Tennakoon, Qiangze Hoi, Peiyong Guan, Audrey S.M. Teo, Wah Heng Lee, Patrick Tan, Win Kin Sung, Pauline Ng, Axel Hillmer
Journal: Blood (2015)
The relatively poor correlation between random and 24-hour urine protein excretion in patients with biopsy-proven glomerular diseases
Authors: Marie C. Hogan, Heather N. Reich, Peter J. Nelson, Sharon G. Adler, Daniel C. Cattran, Gerald B. Appel, Debbie S. Gipson, Matthias Kretzler, Jonathan P. Troost, John C. Lieske
Journal: Kidney International (2016)

Random urine protein creatinine ratios are used to estimate 24-hour urine protein excretion, which is considered a diagnostic gold standard. However, few studies are available of the sensitivity and specificity of this estimation in patients with glomerular proteinuria. To clarify this, we measured the urine protein and creatinine centrally in random and 24-hour urine collections at biopsy and longitudinally every 6 months in individuals participating in the Nephrotic Syndrome Study Network (NEPTUNE) cohort with glomerular disease. In the initial developmental cohort, 302 patients had same day random and 24-hour samples with a total of 827 paired measurements across all visits. The protein excretion (g/day) was higher in adult than pediatric patients. The correlation between the random urine protein creatinine ratio and 24-hour urine protein excretion was moderate in both groups (r of 0.60 and 0.67, respectively). However, the log10 transformation of values strengthened correlations in both groups (r of 0.85 and 0.82, respectively). Associations were moderately stronger among obese patients. Prediction equations were developed and validated in 232 unique cases from NEPTUNE (R2 of 0.65). Thus, in patients with glomerular disease and proteinuria, the urine protein creatinine ratio correlates only moderately with 24-hour urine protein excretion. However an estimating equation was developed to derive 24-hour urine protein excretion from random urine protein creatinine ratio values with improved precision. The long-term prognostic value of log10-transformed random protein creatinine ratios values requires future study.
Histone Deacetylase Inhibition Using LBH589 Is Effective in Lymphoma and Results in Down-Regulation of the NF-KB Pathway.
Authors: Jason L. Smith, Amee Patel, Siyao Fan, Cassandra L. Jacobs, Katherine J. Walsh, Qingquan Liu, David A. Rizzieri, Sandeep Dave
Journal: Blood (2009)
O-015 Association between depth of response (DpR) and survival outcomes in RAS-wild-type (wt) patients with metastatic colorectal cancer (mCRC) receiving first-line FOLFOX or FOLFIRI plus cetuximab once-every-2-weeks in the APEC study
Authors: A.-L. Cheng, G. Cornelio, L. Shen, T. Price, T.-S. Yang, I.-J. Chung, G.-H. Dai, J.-K. Lin, A. Sharma, K.-H. Yeh, B. Ma, A. Zaatar, Z.-Z. Guan, N. Masood, V. Srimuninnimit, T. Yau, F. Beier, S. Chatterjee, R. Lim
Journal: Annals of Oncology (2016)
Cord-Blood Transplantation in Patients with Minimal Residual Disease
Authors: Filippo Milano, Ted Gooley, Brent Wood, Ann Woolfrey, Mary E. Flowers, Kristine Doney, Robert Witherspoon, Marco Mielcarek, Joachim H. Deeg, Mohamed Sorror, Ann Dahlberg, Brenda M. Sandmaier, Rachel Salit, Effie Petersdorf, Frederick R. Appelbaum, Colleen Delaney
Journal: New England Journal of Medicine (2016)

The majority of patients in need of a hematopoietic-cell transplant do not have a matched related donor. Data are needed to inform the choice among various alternative donor-cell sources.
Design, Synthesis and Biological Evaluation of A Boron Containing Retinoid As a Novel Therapeutic Agent for Acute Promyelocytic Leukemia
Authors: Carolina D. Schinke, Bhaskar C Das, Swati Goel, Tushar Bhagat, Sangeeta Nischal, Saverio Minucci, George Kabalka, Robert E. Gallagher, Todd Evans, Leonidas C Platanias, Amit Verma
Journal: Blood (2011)
Pleural Effusions from Patients with Mesothelioma Induce Recruitment of Monocytes and Their Differentiation into M2 Macrophages
Authors: Anne-Laure Chéné, Sènan d’Almeida, Thibaut Blondy, Julie Tabiasco, Sophie Deshayes, Jean-François Fonteneau, Laurent Cellerin, Yves Delneste, Marc Grégoire, Christophe Blanquart
Journal: Journal of Thoracic Oncology (2016)
Weight gain after adjuvant chemotherapy in early breast cancer patients in Istanbul.
Authors: N. S. Turhal, G. Atalay Basaran, N. Yurt, G. Yurtseven, D. Cabuk, M. Teomete, M. Gumus
Journal: Journal of Clinical Oncology (2010)

e11099 Background: Weight gain is a known and unwanted complication of chemotherapy (CT). We observed that the female Turkish breast cancer (BC) patients (pts) frequently gain weight with adjuvant therapy and planned to examine the magnitude of this problem in our early BC pts. Methods: A total of 176 early BC pts who received their adjuvant systemic therapy in Marmara University Hospital between 1998 and 2008 are included in the study. We recorded their weight before and after CT and also a year after CT to find out whether the change with weight is transitory. We have also recorded demographic information, including their educational level, menopausal status, the type of CT or hormonal treatment, stage of disease, marital status, occupation and the underlying diseases to analyze the relationship between change in weight and these parameters. Results: Median age of pts is 53 and 72% of pts were postmenopausal. Educational level is equally distributed for primary education (%27), high school (%40) and university and above (33%). The majority are (76%) married, have two children (69%) and house wife (60%). Family history of any cancer is high (32%). Most of the pts had stage II cancer (56%), received anthracyclines ± taxane based CT (98%) and has no underlying disease (68%). The majority does not smoke (73%) or drink alcohol (93%). Pts who gain weight or not were represented the 78% and 22% of our study population respectively. Mean weight before the CT was 68.9 kg and increased to 70.6 upon completion of CT (p = 0.000). A year after completion of CT it increased to 71.9 kg. (p = 0.000). Mean body mass index (BMI) was 27.1 at baseline and significantly higher one year after completion of CT (BMI 27.8, p = 0.000) and one year after CT (BMI:28.3, p = 0.000). Age, menaopausal status, multiparity and presenence of comorbid diseases had statistically significant impact on weight gain following adjuvant therapy in BC pts. Conclusions: This study shows that Turkish women with early BC gain weight after adjuvant systemic therapy, in line with European and American counterparts. Given the adverse consequences of weight, it is imperative to inform pts about this change and to develop strategies for weight maintenance during and after systemic therapy. No significant financial relationships to disclose.
The Silk Robe
Authors: Jack Coulehan
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Potentiation of Peptide Receptor Radionuclide Therapy by the PARP Inhibitor Olaparib
Authors: Julie Nonnekens, Melissa van Kranenburg, Cecile E.M.T. Beerens, Mustafa Suker, Michael Doukas, Casper H.J. van Eijck, Marion de Jong, Dik C. van Gent
Journal: Theranostics (2016)

Metastases expressing tumor-specific receptors can be targeted and treated by binding of radiolabeled peptides (peptide receptor radionuclide therapy or PRRT).For example, patients with metastasized somatostatin receptor-positive neuroendocrine tumors (NETs) can be treated with radiolabeled somatostatin analogues, resulting in strongly increased progression-free survival and quality of life.There is nevertheless still room for improvement, as very few patients can be cured at this stage of disease.We aimed to specifically sensitize replicating tumor cells without further damage to healthy tissues.Thereto we investigated the DNA damaging effects of PRRT with the purpose to enhance these effects through modulation of the DNA damage response.Although PRRT induces DNA double strand breaks (DSBs), a larger fraction of the induced lesions are single strand breaks (expected to be similar to those induced by external beam radiotherapy) that require poly-[ADP-ribose]-polymerase 1 (PARP-1) activity for repair.If these breaks cannot be repaired, they will cause replication fork arrest and DSB formation during replication.Therefore, we used the PARP-1 inhibitor Olaparib to increase the number of cytotoxic DSBs.Here we show that this new combination strategy synergistically sensitized somatostatin receptor expressing cells to PRRT.We observed increased cell death and reduced cellular proliferation compared to the PRRT alone.The enhanced cell death was caused by increased numbers of DSBs that are repaired with remarkably slow kinetics, leading to genome instability.Furthermore, we validated the increased DSB induction after PARP inhibitor addition in the clinically relevant model of living human NET slices.We expect that this combined regimen can thus augment current PRRT outcomes.
Where is the leadership we need?
Authors: Fiona Godlee
Journal: BMJ (2016)

The BMA’s decision to call off next week’s five day strike by junior doctors in England has been widely greeted with a sigh of relief. The BMA says it acted after it was contacted last week by thousands of its members worried that the strike would put patients at risk (doi:10.1136/bmj.i4844).

This sensible decision restores a degree of professionalism to a sorry and damaging saga. But, asks Andy Cowper (doi:10.1136/bmj.i4846), will public sympathy for the juniors outlast the government’s determination to enforce the new contract? Is this still a contractual dispute, or has it morphed into a political attack on …
Anticancer Effects of Targeting Hsp70 in Tumor Stromal Cells
Authors: Vladimir L. Gabai, Julia A. Yaglom, Yongmei Wang, Le Meng, Hao Shao, Geunwon Kim, Teresa Colvin, Jason Gestwicki, Michael Y. Sherman
Journal: Cancer Research (2016)

The stress-induced chaperone protein Hsp70 enables the initiation and progression of many cancers, making it an appealing therapeutic target for development. Here, we show that cancer cells resistant to Hsp70 inhibitors in vitro remain sensitive to them in vivo, revealing the pathogenic significance of Hsp70 in tumor stromal cells rather than tumor cells as widely presumed. Using transgenic mouse models of cancer, we found that expression of Hsp70 in host stromal cells was essential to support tumor growth. Furthermore, genetic ablation or pharmacologic inhibition of Hsp70 suppressed tumor infiltration by macrophages needed to enable tumor growth. Overall, our results illustrate how Hsp70 inhibitors mediate the anticancer effects by targeting both tumor cells and tumor stromal cells, with implications for the broad use of these inhibitors as tools to ablate tumor-associated macrophages that enable malignant progression. Cancer Res; 76(20); 5926-32. ©2016 AACR.
Disruptive ARID1A Mutations in Follicular Lymphoma Impair DNA Repair Efficiency and Are Associated with Favorable Outcome in Patients Receiving First-Line Immunochemotherapy
Authors: Deepak Bararia, Michael Heide, Robert S. Welner, Tatiana Romashova, Alessandro Pastore, Radhika Mathur, Randy D. Gascoyne, Robert Kridel, Boris G. Willson, Charles W.M. Roberts, Wolfgang Hiddemann, David M Weinstock, Oliver Weigert
Journal: Blood (2015)
Sedation Protocol for Critically Ill Pediatric Patients—Reply
Authors: Martha A. Q. Curley, David Wypij, Michael A. Matthay
Journal: JAMA (2015)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Genetically Predicted Body Mass Index and Breast Cancer Risk: Mendelian Randomization Analyses of Data from 145,000 Women of European Descent
Authors: Yan Guo, Shaneda Warren Andersen, Xiao-Ou Shu, Kyriaki Michailidou, Manjeet K. Bolla, Qin Wang, Montserrat Garcia-Closas, Roger L. Milne, Marjanka K. Schmidt, Jenny Chang-Claude, Allison Dunning, Stig E. Bojesen, Habibul Ahsan, Kristiina Aittomäki, Irene L. Andrulis, Hoda Anton-Culver, Volker Arndt, Matthias W. Beckmann, Alicia Beeghly-Fadiel, Javier Benitez, Natalia V. Bogdanova, Bernardo Bonanni, Anne-Lise Børresen-Dale, Judith Brand, Hiltrud Brauch, Hermann Brenner, Thomas Brüning, Barbara Burwinkel, Graham Casey, Georgia Chenevix-Trench, Fergus J. Couch, Angela Cox, Simon S. Cross, Kamila Czene, Peter Devilee, Thilo Dörk, Martine Dumont, Peter A. Fasching, Jonine Figueroa, Dieter Flesch-Janys, Olivia Fletcher, Henrik Flyger, Florentia Fostira, Marilie Gammon, Graham G. Giles, Pascal Guénel, Christopher A. Haiman, Ute Hamann, Maartje J. Hooning, John L. Hopper, Anna Jakubowska, Farzana Jasmine, Mark Jenkins, Esther M. John, Nichola Johnson, Michael E. Jones, Maria Kabisch, Muhammad Kibriya, Julia A. Knight, Linetta B. Koppert, Veli-Matti Kosma, Vessela Kristensen, Loic Le Marchand, Eunjung Lee, Jingmei Li, Annika Lindblom, Robert Luben, Jan Lubinski, Kathi E. Malone, Arto Mannermaa, Sara Margolin, Frederik Marme, Catriona McLean, Hanne Meijers-Heijboer, Alfons Meindl, Susan L. Neuhausen, Heli Nevanlinna, Patrick Neven, Janet E. Olson, Jose I. A. Perez, Barbara Perkins, Paolo Peterlongo, Kelly-Anne Phillips, Katri Pylkäs, Anja Rudolph, Regina Santella, Elinor J. Sawyer, Rita K. Schmutzler, Caroline Seynaeve, Mitul Shah, Martha J. Shrubsole, Melissa C. Southey, Anthony J. Swerdlow, Amanda E. Toland, Ian Tomlinson, Diana Torres, Thérèse Truong, Giske Ursin, Rob B. Van Der Luijt, Senno Verhoef, Alice S. Whittemore, Robert Winqvist, Hui Zhao, Shilin Zhao, Per Hall, Jacques Simard, Peter Kraft, Paul Pharoah, David Hunter, Douglas F. Easton, Wei Zheng
Journal: PLoS Medicine (2016)

Observational epidemiological studies have shown that high body mass index (BMI) is associated with a reduced risk of breast cancer in premenopausal women but an increased risk in postmenopausal women. It is unclear whether this association is mediated through shared genetic or environmental factors.
Characterization of progressive HIV-associated tuberculosis using 2-deoxy-2-[18F]fluoro-D-glucose positron emission and computed tomography
Authors: Hanif Esmail, Rachel P Lai, Maia Lesosky, Katalin A Wilkinson, Christine M Graham, Anna K Coussens, Tolu Oni, James M Warwick, Qonita Said-Hartley, Coenraad F Koegelenberg, Gerhard Walzl, JoAnne L Flynn, Douglas B Young, Clifton E Barry III, Anne O'Garra, Robert J Wilkinson
Journal: Nature Medicine (2016)
Using Neuroscience to Help Understand Fear and Anxiety: A Two-System Framework
Authors: Joseph E. LeDoux, Daniel S. Pine
Journal: American Journal of Psychiatry (2016)

Tremendous progress has been made in basic neuroscience in recent decades. One area that has been especially successful is research on how the brain detects and responds to threats. Such studies have demonstrated comparable patterns of brain-behavior relationships underlying threat processing across a range of mammalian species, including humans. This would seem to be an ideal body of information for advancing our understanding of disorders in which altered threat processing is a key factor, namely, fear and anxiety disorders. But research on threat processing has not led to significant improvements in clinical practice. The authors propose that in order to take advantage of this progress for clinical gain, a conceptual reframing is needed. Key to this conceptual change is recognition of a distinction between circuits underlying two classes of responses elicited by threats: 1) behavioral responses and accompanying physiological changes in the brain and body and 2) conscious feeling states reflected in self-reports of fear and anxiety. This distinction leads to a “two systems” view of fear and anxiety. The authors argue that failure to recognize and consistently emphasize this distinction has impeded progress in understanding fear and anxiety disorders and hindered attempts to develop more effective pharmaceutical and psychological treatments. The two-system view suggests a new way forward.
Trajectory of cognitive impairment during breast cancer treatment: A prospective analysis
Authors: L. I. Wagner, J. J. Sweet, Z. Butt, J. Beaumont, K. A. Havlin, T. Sabatino, D. Cella
Journal: Journal of Clinical Oncology (2006)

8500 Background: Several studies havedocumented cognitive impairment in cancer patients; however these reports are primarily based on cross-sectional comparisons. Prospective evaluation would better elucidate the onset and course of cognitive dysfunction related to chemotherapy. Methods: Of 72 breast cancer patients enrolled, 51 completed a comprehensive neuropsychological battery before chemotherapy (T1), on Day 1 of Cycle 4 (T2), and at 6-month follow-up (T3). Participants scoring ≥ 1 SD below the normative mean on ≥ 3 neuropsychological tests OR ≥ 2 SD below on 1 test were classified as impaired. Reliable change indices (RCI) conservatively estimated significant change over time. Results: Participants were White (70.6%) females (96.1%) with a mean of 15.9 ± 2.3 years of education. Mean age was 51.6 ± 8.6 years and most had Stage II (78%) or Stage III (16%) disease. Hospital Anxiety and Depression Scale scores were in the normal range at all assessments and were unrelated to T1 cognitive impairment. Consistent with previous research, 9 (17.6%) of patients met criteria for cognitive impairment at T1. By T2, 14 (27.4%) were cognitively impaired; however, at T3 follow up only 5 (9.8%) were impaired. As noted in the table, most impairment occurs during chemotherapy. Among patients not impaired before chemotherapy it was uncommon for impairment at T2 to persist at follow-up. Conclusions: Some breast cancer patients indeed develop cognitive impairment during treatment, much of which appears to resolve at 6 months. Domains most affected include attention, visuospatial skills, and working memory. Attention problems resolved by 6 months, while working memory and visuospatial deficits persisted. [Table: see text] No significant financial relationships to disclose.
Aberrant splicing and drug resistance in AML
Authors: Rosalia de Necochea-Campion, Geoffrey P. Shouse, Qi Zhou, Saied Mirshahidi, Chien-Shing Chen
Journal: Journal of Hematology & Oncology (2016)

The advent of next-generation sequencing technologies has unveiled a new window into the heterogeneity of acute myeloid leukemia (AML). In particular, recurrent mutations in spliceosome machinery and genome-wide aberrant splicing events have been recognized as a prominent component of this disease. This review will focus on how these factors influence drug resistance through altered splicing of tumor suppressor and oncogenes and dysregulation of the apoptotic signaling network. A better understanding of these factors in disease progression is necessary to design appropriate therapeutic strategies recognizing specific alternatively spliced or mutated oncogenic targets.